Fertoz Limited

FTZ

Fertoz Ltd. engages in the exploration, development, and marketing of regenerative and organic fertilizer products. The company is headquartered in Melbourne, Victoria. The company went IPO on 2013-09-02. The firm provides carbon credits developed from nature-based projects developed globally. The company has two rock phosphate mining projects in Canada: Wapiti and Fernie. The Wapiti Mining Project encompasses an area of over 12,000 hectares containing extensive rock phosphate zones. The Fernie Mining Project is made up of groups of claims at Marten, Barnes Lake, Crowsnest/Pump Station, Mt. Lyne, Graves/North Alexander, Alexander, Bighorn, Lodgepole and Lizzard. The sites are located near Sparwood, the Elk River community in British Columbia, and totals around 10,000 hectares. Its products include Rock Phosphate - powder, Rock Phosphate - micronized, Rock Phosphate - granulated and Fertify - pelleted. The firm also markets its products in the United States and Mexico.

Kairos Minerals Limited

KAI

Kairos Minerals Ltd. engages in mining and exploration of resources. The firm owns 100% of the flagship 1.38Mozs Mt York Gold Project, which is an advanced gold deposit located 100 kilometers (km) south of Port Hedland in Tier 1 gold country. The project is four km south of Pilbara Minerals’ Pilgangoora Lithium-Tantalum Mine and occurs in the same prolific greenstone belt. Its 100%-owned Roe Hills Project, located 120 km east of Kalgoorlie in Western Australia’s Eastern Goldfields, comprises an extensive tenement portfolio where the Company’s exploration work has confirmed the potential for significant discoveries of high-grade gold, nickel, cobalt, lithium and rare earth mineralization. The company has also discovered significant high-grade rare earth element (REE) mineralization at Black Cat within enriched lower saprolite clays overlying fertile REE-bearing syenite intrusions.

Lake Resources N.L.

LKE

Lake Resources NL, is a lithium exploration company, which is focused on exploring lithium basins and pegmatites in Argentina. The company is headquartered in Sydney, New South Wales. The company went IPO on 2001-08-29. The firm also has three additional early-stage projects in this region, including Olaroz, Cauchari and Pasode Jama. The flagship Kachi Project is located in Argentina’s Catamarca Province at the southern end of the Lithium Triangle. The project comprises 705 square kilometers (Km2) of leases and lease applications over a brine-bearing basin 20 kilometers (km) long, 15 km wide and 400-800 meter deep centered. The Cauchari Lithium Brine Project in Jujuy Province. The Paso de Jama Lithium Brine Project in Jujuy Province is comprised of over 59,000 hectares. The Olaroz Lithium Brine Project covers 45,000 hectares.

Parkway Corporate Limited

PWN

Parkway Corporate Ltd. is an exploration company, which engages in the commercialization of proprietary brine processing technologies. The firm operates through four core business units: Parkway Process Solutions (PPS), Parkway Process Technologies (PPT), Queensland Brine Solutions (QBS) and Parkway Ventures (PV). Its PPS division is a provider of industrial water treatment products, services, solutions and associated technology to customers throughout Australia. The company also offers engineering solutions. PPT is a technology development, acquisition, and commercialization division, which owns a portfolio of industrial wastewater treatment technologies, including the patented aMES and iBC process technologies. QBS is focused on addressing the coal seam gas derived waste brine and salt challenges in Queensland. PV holds a portfolio of project equity interests, including interests relating to its Karinga Lakes Potash Project in the Northern Territory of Australia.

Dimerix Limited

DXB

Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. The company develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The firm is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets.